Background: Approximately 15% of migraine sufferers need preventative medicine because they have more than two episodes each month. Migraine is a regular, persistent condition that frequently makes victims helpless. Numerous drugs from various classes have so far been used in migraine prophylaxis. Their effectiveness is recurrently overshadowed by their side effects because they must be used for a long time, which occasionally necessitates stopping the drug.
Materials And Methods: In the tertiary care teaching hospital's department of medicine, a prospective, comparative, open-label study was initiated. Two groups of 80 patients were randomly chosen. For 3 months, the 40 patients in Group A were given a tablet of amitriptyline 10 mg once daily, whereas the 40 patients in Group B were given a tablet of propranolol 20 mg once a day. At the conclusion of the fourth, eighth, and twelfth weeks, the patients' own self-assessment migraine diary and a 4-point pain scale were used to grade the intensity of the headaches.
Results: As a result, in Group A, the mean migraine attack severity in periods 1 and 2 was 5.88 2.69 and 5.41 2.48, respectively. In Group B, the mean was 5.15 2.75 in period 1 and 5.66 2.78 in period 2, respectively. The average length of a migraine attack in Group A was 20.30 5.61 h in period 1 and 16.75 5.23 h in period 2. In Group B, the mean was 16.59 3.21 in period 1 and 18.78 5.14 in period 2. Between groups A and B, there was a statistically significant difference.
Conclusion: The average number of migraine attacks reduced in the amitriptyline and propranolol groups as the treatment duration increased. Amitriptyline is a popular medication with established effectiveness and manageable levels of negative side effects. It is the tricyclic antidepressant that is most frequently used to prevent headaches. When administered for migraine prevention, it generates a quick response within 3 months. Propranolol is less effective than amitriptyline at reducing the frequency, length, and severity of episodes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11006045 | PMC |
http://dx.doi.org/10.4103/jfmpc.jfmpc_927_23 | DOI Listing |
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
Research Center of Neurology, Moscow, Russia.
Objective: To evaluate the relationship of diet and food components with the frequency of migraine attacks.
Material And Methods: Sixty patients (mean age 35.5±8.
Headache
December 2024
Department of Physical Therapy, University of Florida, Gainesville, Florida, USA.
Objective: To develop and assess the psychometrics of the Chronic Headache Self-Efficacy Scale (CHASE).
Background: Existing scales assess self-efficacy in coping strategies and management of symptoms and triggers but do not measure other important self-efficacy domains, such as performing daily activities and socializing in patients with chronic daily headache (CDH).
Methods: The study had two phases: (i) Development of the 14-item CHASE, with items derived from patients with CDH and a multidisciplinary healthcare team; (ii) longitudinal observational study for psychometric evaluation.
Sci Rep
December 2024
Departamento de Cirugía, Ciencias Médicas y Sociales, Facultad de Medicina, Universidad de Alcalá, Alcalá de Henares, Spain.
Previous research has focused on the possibility of cervical dysfunction in migraine patients, similar to what is observed in patients with tension-type headaches. However, there is no evidence concerning the physical function of other body regions, even though lower levels of physical activity have been reported among migraine patients. The aim of this study was to compare cervical and extra-cervical range of motion, muscular strength, and endurance, as well as overall levels of physical activity, between patients with chronic migraine (CM) and asymptomatic participants.
View Article and Find Full Text PDFToxins (Basel)
December 2024
Headache Center, Neurological Clinic, "L. Amaducci", AOUC Policlinico, Piazza G. Cesare, 11, 70124 Bari, Italy.
This Special Issue aims to provide an updated overview of the current state and future perspectives of botulinum toxin treatment for migraine [...
View Article and Find Full Text PDFNeurol Int
December 2024
Universidad Simón Bolívar, Facultad de Ciencias de la Salud, Barranquilla 080001, Atlántico, Colombia.
Background: Ophthalmoplegic migraine (OM) is an uncommon variant of migraine characterised by headache and cranial nerve palsy, posing significant diagnostic and therapeutic challenges.
Objective: This study aimed to describe an extremely rare OM variant with a partial therapeutic response.
Clinical Case: A 34-year-old pregnant woman in gestational week 19.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!